Preoperative coagulation assessment of patients on apixaban and rivaroxaban undergoing hip fracture surgery by chromogenic antiXa assays and rotational thrombelastometry (ROTEM®)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00008834

Enrollment

100

Registered

2016-03-16

Start date

2016-04-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip fracture S72.9

Interventions

Group 1: In patients with hip fracture that take apixaban antiXa- and ROTEM-measurements will be performed. Group 2: In patients with hip fracture that take rivaroxaban antiXa- and ROTEM-measurements

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Intake of apixaban or rivaroxaban and planned hip fracture surgery

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Specific antiXa values will be measured at certain time points (as described below) and analysed for possible correlation with intraoperative blood loss. Time points of blood sampling: admission, 24 and 48 hours after the last intake of medication (apixaban or rivaroxaban) and at the time of surgery. Measurement: Chromogenic antiXa measurement will be performed on a STA-R Evolution coagulometer (Diagnostica Stago S.A.S., Asnières sur Seine, France) in citrated plasma obtained by centrifugation. BIOPHEN DiXa-I (Hyphen-Biomed, Neuville-sur-Oise, France) will be used for the measurements.	—

Measure

Time frame

Specific antiXa values will be measured at certain time points (as described below) and analysed for possible correlation with intraoperative blood loss. Time points of blood sampling: admission, 24 and 48 hours after the last intake of medication (apixaban or rivaroxaban) and at the time of surgery. Measurement: Chromogenic antiXa measurement will be performed on a STA-R Evolution coagulometer (Diagnostica Stago S.A.S., Asnières sur Seine, France) in citrated plasma obtained by centrifugation. BIOPHEN DiXa-I (Hyphen-Biomed, Neuville-sur-Oise, France) will be used for the measurements.

—

Secondary

Measure	Time frame
LowTF-ROTEM® at the time of surgery will be analysed for possible correlation with intraoperative blood loss.	—

Countries

Austria

Contacts

Public ContactJohannes Gratz

Medizinische Universität WienUniversitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie

johannes.gratz@meduniwien.ac.at+43-40400-41500

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026